Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 236

1.

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.

LeWitt PA, Verhagen Metman L, Rubens R, Khanna S, Kell S, Gupta S.

Clin Neuropharmacol. 2018 Mar/Apr;41(2):47-55. doi: 10.1097/WNF.0000000000000269.

2.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Review.

PMID:
29237794
3.

The Effect of Botulinum Toxin on Network Connectivity in Cervical Dystonia: Lessons from Magnetoencephalography.

Mahajan A, Alshammaa A, Zillgitt A, Bowyer SM, LeWitt P, Kaminski P, Sidiropoulos C.

Tremor Other Hyperkinet Mov (N Y). 2017 Nov 10;7:502. doi: 10.7916/D84M9H4W. eCollection 2017.

4.

Portrayal of progressive supranuclear palsy in the 16th century.

LeWitt P.

Lancet Neurol. 2017 Dec;16(12):956-957. doi: 10.1016/S1474-4422(17)30366-6. Epub 2017 Nov 14. No abstract available.

PMID:
29165255
5.

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H.

J Aerosol Med Pulm Drug Deliv. 2017 Nov 21. doi: 10.1089/jamp.2016.1354. [Epub ahead of print]

PMID:
29161531
6.

Multimodal Imaging in a Patient with Hemidystonia Responsive to GPi Deep Brain Stimulation.

Sidiropoulos C, Bowyer SM, Zillgitt A, LeWitt PA, Bagher-Ebadian H, Davoodi-Bojd E, Schwalb JM, Rammo R, Air E, Soltanian-Zadeh H.

Case Rep Neurol Med. 2017;2017:9653520. doi: 10.1155/2017/9653520. Epub 2017 Jul 4.

7.

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

Trosch RM, Espay AJ, Truong D, Gil R, Singer C, LeWitt PA, Lew MF, Tagliati M, Adler CH, Chen JJ, Marchese D, Comella CL.

J Neurol Sci. 2017 May 15;376:84-90. doi: 10.1016/j.jns.2017.02.042. Epub 2017 Feb 21.

8.

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2017 Apr 3;9:89. doi: 10.3389/fnagi.2017.00089. eCollection 2017.

9.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A.

JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

10.

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators.

Neurology. 2017 Feb 28;88(9):862-869. doi: 10.1212/WNL.0000000000003663. Epub 2017 Feb 8.

11.

GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.

Sidiropoulos C, LeWitt PA, Odekerken VJ, Schuurman PR, de Bie RM.

Neurology. 2016 Aug 16;87(7):745-6. doi: 10.1212/WNL.0000000000003027. No abstract available.

PMID:
27527541
12.

Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2016 Jul 26;8:178. doi: 10.3389/fnagi.2016.00178. eCollection 2016.

13.

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.

Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE.

Lancet Neurol. 2016 Aug;15(9):954-966. doi: 10.1016/S1474-4422(16)30079-5. Review.

PMID:
27478953
14.

Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?

Loeffler DA, LeWitt PA, Camp DM.

Mov Disord. 2016 Aug;31(8):1134-8. doi: 10.1002/mds.26711. Epub 2016 Jul 14. Review. No abstract available.

15.

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Hampson NB, Kieburtz KD, LeWitt PA, Leinonen M, Freed MI.

Int J Neurosci. 2017 Mar;127(3):276-284. doi: 10.1080/00207454.2016.1194274. Epub 2016 Jun 27.

PMID:
27345931
16.

Intraoperative MRI for deep brain stimulation lead placement in Parkinson's disease: 1 year motor and neuropsychological outcomes.

Sidiropoulos C, Rammo R, Merker B, Mahajan A, LeWitt P, Kaminski P, Womble M, Zec A, Taylor D, Wall J, Schwalb JM.

J Neurol. 2016 Jun;263(6):1226-31. doi: 10.1007/s00415-016-8125-0. Epub 2016 Apr 28.

PMID:
27126457
17.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD.

Mov Disord. 2016 Sep;31(9):1356-65. doi: 10.1002/mds.26611. Epub 2016 Apr 19.

PMID:
27090868
18.

Levodopa therapy for Parkinson disease: A look backward and forward.

LeWitt PA, Fahn S.

Neurology. 2016 Apr 5;86(14 Suppl 1):S3-12. doi: 10.1212/WNL.0000000000002509. Epub 2016 Apr 4. Review.

PMID:
27044648
19.

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L.

Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133.

20.

CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Loeffler DA, Smith LM, Coffey MP, Aasly JO, LeWitt PA.

J Neural Transm (Vienna). 2016 Mar;123(3):179-87. doi: 10.1007/s00702-015-1479-0. Epub 2015 Nov 3.

PMID:
26526034

Supplemental Content

Loading ...
Support Center